What Nal Von Minden does

Nal von minden GmbH is a German in-vitro diagnostics manufacturer specializing in rapid lateral-flow tests for medical and toxicology applications. Founded in 1982 as von Minden GmbH in Moers and restructured into its current form via the 2008 merger with nal24 GmbH, the company operates from seven European locations and employs 230+ people across 20+ nationalities. Its portfolio spans two core brands: NADAL® medical rapid tests (respiratory, gastrointestinal, infectious disease, cardiology, tumor markers, gynecology, and urine test strips) and Drug-Screen® toxicology tests (urine, saliva, and blood formats with up to 35 drug parameters in cassette, dip, and cup formats), complemented by Point-of-Care instrument platforms (NADAL PCR Analyzer PRO1, AFIAS, LensHooke X3 PRO). Manufacturing is conducted at the company's own automated CERES POC facility in Göttingen, Germany, capable of producing up to 2 million tests per month, with products sold under IVDR and EN ISO 13485 quality certifications exclusively to professional users via direct country-specific sales teams covering DACH, Western Europe, the Nordics, the UK, Italy, Poland, and Latin America export markets. The company monetizes through unit-priced B2B sales of consumables, hardware sales of POCT devices (with recurring consumable revenue), and contract manufacturing services for third-party IVD developers. Customers include physician practices, hospitals, pharmacies, laboratories, police and prisons, judicial authorities, health authorities, drug rehabilitation centers, foster care agencies, and industrial occupational health programs, with no single anchor customer disclosed.

Name

Nal Von Minden

Legal name

nal von minden GmbH

Website

https://nal-vonminden.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

101–250 employees

Short description

Nal von minden is a German in-vitro diagnostics manufacturer producing NADAL® medical rapid tests, Drug-Screen® toxicology tests, and Point-of-Care devices, sold B2B exclusively to healthcare providers, government agencies, law enforcement, and industrial customers across Europe and Latin America.

Ownership category

akta.pro rank

Product category

In-Vitro Diagnostics

NAICS

Medical Equipment and Supplies Manufacturing (3391), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

akta.pro secondary industry

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• In-vitro diagnostics
• Rapid diagnostic tests
• Drug screening tests
• Point-of-care devices
• Lateral flow assays

Headquarters

HQ city

Deagu De Jos

HQ country

Romania

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Rapid Diagnostic Test Sales: Sale of medical rapid tests and drug screening tests in various formats (dip tests, cassette tests, cup tests). Products sold directly to healthcare providers, government agencies, and industrial customers via B2B sales model.
2. Point-of-Care Device Sales: Sale and distribution of POCT equipment including NADAL PCR Analyzer PRO1, AFIAS devices, and LensHooke sperm analysis devices with device-specific consumable tests.
3. Contract Manufacturing Services: Custom rapid test manufacturing services for third parties. Offers upstream (uncut sheet production), downstream (assembly and packaging), and individual process steps including membrane coating and bioconjugation. Serves both prototype and large-scale production needs.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Nal von minden develops, manufactures, and distributes in-vitro diagnostic rapid tests under the NADAL brand (covering infectious disease, gastrointestinal, respiratory, cardiology, tumor markers, gynecology, and blood analysis) and the Drug-Screen brand (urine, saliva, and blood drug-screening tests with 35+ parameters). It also distributes Point-of-Care diagnostic devices (NADAL PCR Analyzer PRO1, AFIAS, LensHooke X3 PRO) and offers contract manufacturing services from its CERES POC automated production facility in Göttingen, Germany, selling exclusively to professional users (medical, government, industrial) across Europe and selected export markets.

Product overview

Nal Von Minden is a specialist in in-vitro diagnostics offering a comprehensive portfolio of rapid tests and Point-of-Care diagnostic systems. The company operates two main product brands: NADAL® for medical rapid tests (including gastrointestinal diagnostics, infectious disease testing, respiratory panels, and clinical chemistry) and Drug-Screen® for toxicology/drug screening (offering urine, saliva, and blood tests with over 35 parameters in multiple formats). The portfolio is complemented by Point-of-Care devices including the NADAL® PCR Analyzer PRO1 for molecular diagnostics, AFIAS automated testing platform, and LensHooke® X3 PRO sperm analysis device. The company operates its own fully automated production facility (CERES POC) in Göttingen, Germany, enabling contract manufacturing services for rapid tests. All products are manufactured in Germany with ISO 13485 certified quality management.

Differentiator

Problem solved

Functional benefit

Brands

• NADAL: Brand for rapid medical tests including COVID-19, influenza, and other diagnostic tests.
• Drug-Screen
• AFIAS
• LensHooke
• self-diagnostics

Products and services

• NADAL® COVID-19, Influenza A/B & RSV Combination Test Combination lateral-flow rapid test for simultaneous detection of COVID-19, Influenza A/B, and RSV antigens, intended for professional point-of-care use by healthcare providers and clinical laboratories.
• NADAL® Norovirus GI/GII + Rota-Adenovirus Test Cassette Cassette-format stool rapid test for simultaneous detection of Norovirus GI/GII, Rotavirus, and Adenovirus, intended for clinical gastrointestinal diagnostics.
• NADAL® C. difficile Toxin A/B Stool Test Rapid stool cassette test for detection of Clostridioides difficile toxins A and B, used by hospitals and laboratories for initial screening.
• NADAL® Strep A plus Test Rapid test for detection of Group A Streptococcus antigen from throat swabs, used in physician offices and emergency settings for fast differential diagnosis.
• NADAL® Influenza A/B Test Cassette Rapid test cassette for detection of Influenza A and B antigens from respiratory samples, for clinical and point-of-care professional use.
• NADAL® Adenovirus & RSV Combination Rapid Test Combination rapid test for simultaneous detection of Adenovirus and Respiratory Syncytial Virus (RSV) antigens from respiratory specimens.
• NADAL® Enterovirus-Antigen VP1-Peptid Stool Test Stool test cassette for detection of Enterovirus antigen using VP1-peptide capture, for clinical gastrointestinal diagnostics.
• NADAL® Salmonella spp. Stool Test Rapid stool test cassette for detection of Salmonella species, used in clinical diagnostics and food-borne illness screening.
• NADAL® E. coli O157 Stool Test Rapid stool test cassette for detection of E. coli O157, intended for clinical diagnostics of enterohemorrhagic infections.
• NADAL® PCR Analyzer PRO1 Point-of-Care PCR testing device delivering laboratory-quality molecular infectious-disease diagnostics at the point of care, sold with device-specific consumables.
• AFIAS Point-of-Care Testing System Automated Point-of-Care immunoassay platform for emergency parameters, tumor markers, and various clinical diagnostics, used with device-specific consumable tests.
• LensHooke® X3 PRO Sperm Analysis Device Point-of-Care device for sperm analysis, evaluating five key parameters of sperm quality directly at the point of care for fertility clinics and andrology practices.
• Drug-Screen® Multi Series Drug Rapid Tests Multi-parameter drug rapid tests covering 35+ substances and metabolites in cup, cassette, and dipstick formats for urine samples, intended for professional use in healthcare, forensic, occupational, and law-enforcement settings.
• Drug-Screen® Saliva Tracer Tests Minimally invasive saliva-based drug screening tests with tamper-proof design, detecting up to 20 drug parameters from a single saliva sample.
• Drug-Screen® Urine Single Test Strips and Cassettes Single-parameter urine test strips and cassettes for individual drug detection (methamphetamine, cannabinoids, morphine/opiates, cocaine, benzodiazepines, amphetamine, and others), available in multiple cut-off levels.
• ESA Substance Identification Tests Substance identification tests (ESA color-change tests and high-sensitivity TraceDetect tests) for identification of unknown powders, tablets, and liquids, distributed to law enforcement, forensics, and clinical users via subsidiary ESA Test GmbH.
• Contract Manufacturing Services for Rapid Tests Contract manufacturing services for third-party rapid tests, offering upstream (uncut sheet production), downstream (assembly and packaging), and individual process steps including membrane coating and bioconjugation for both prototype and large-scale production.

Quantifiable outcome

• Up to 99% specificity for drug screening tests
• +3 more outcomes

Named customers11 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• ESA Test GmbHcoreStrategic or Co-development Partner · 1 January 2015ESA Test GmbH, a Thuringian traditional company specializing in substance testing, became a 100% subsidiary of nal von minden GmbH in 2015. The company handles substance tests for detecting unknown powders, tablets, and liquids.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Abbott Rapid Diagnostics: Abbott's diagnostics division (including the former Alere rapid-diagnostics business) is the global market leader in lateral-flow rapid tests including drug screening, infectious disease, and POCT — directly comparable to Nal Von Minden's core NADAL and Drug-Screen product lines.
• Roche Diagnostics: Global diagnostics leader with broad infectious disease and POCT offerings (e.g., cobas Liat, rapid antigen tests) — overlapping with Nal Von Minden's infectious disease and POCT product lines as part of a much wider diagnostics portfolio.
• Siemens Healthineers: Global diagnostics and POCT provider with blood gas, immunoassay, and rapid-testing systems (e.g., epoc, CLINITEST) — comparable to Nal Von Minden's AFIAS and NADAL PCR Analyzer POCT device business within a much larger portfolio.

Direct peers

• QuidelOrtho: QuidelOrtho specializes in rapid diagnostic testing including lateral-flow immunoassays, Sofia POCT platforms, and infectious disease panels — a direct peer in rapid IVD manufacturing and POCT device-plus-consumable business models.
• SD Biosensor: South Korean IVD manufacturer focused on rapid diagnostic tests (COVID, influenza, drug screening) and POCT instruments — closely comparable to Nal Von Minden on rapid-test catalog, POCT devices, and global export orientation.
• Acon Laboratories: US-based manufacturer of lateral-flow rapid diagnostic tests including drug-of-abuse screening and infectious disease panels, with global distribution — directly comparable product portfolio to Nal Von Minden's Drug-Screen and NADAL lines.
• Hangzhou AllTest Biotech: Chinese manufacturer specializing in rapid diagnostic test kits including drug abuse, infectious disease, and women's health panels — directly comparable lateral-flow IVD catalog targeting professional B2B customers globally.
• LumiraDx: POCT platform company offering a microfluidic rapid-testing instrument and consumable menu (infectious disease, cardiac, coagulation) — directly comparable to Nal Von Minden's AFIAS and NADAL PCR Analyzer device-plus-consumable model.
• Response Biomedical: Canadian rapid diagnostic test manufacturer focused on lateral-flow cardiac markers, infectious disease, and drug screening — comparable product mix and B2B distribution model to Nal Von Minden.
• Jant Pharmacal: US distributor and manufacturer of rapid drug-of-abuse screening tests and clinical diagnostics — directly comparable to Nal Von Minden's Drug-Screen toxicology product line in the professional-use rapid test category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCKfGO7acEqtKK-8Y8YQImFQ/featured
• Facebookfacebook.com/nalvonmindenGmbH
• LinkedInlinkedin.com/company/nal-von-minden
• Instagraminstagram.com/nvm_diagnostics
• Xx.com/nvm_diagnostics

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nal Von Minden